Table 3: Effect of GBE treatment on hepatic and pancreatic oxidative stress markers of rats in experimental groups.

N group D group N + G group D + LG groupD + MG group D + HG group D + GLI group

Liver
 GSH (μg/mg protein)512.36 ± 91.25365.50 ± 84.77a529.36 ± 101.23b400.28 ± 79.46451.33 ± 89.44c486.36 ± 98.31b482.09 ± 106.30c
 CAT (U/mg protein)362.63 ± 18.52302.05 ± 22.82a374.47 ± 26.36b313.25 ± 24.47322.52 ± 17.52c349.96 ± 25.01b344.80 ± 20.91b
 SOD (U/mg protein)542.35 ± 24.21235.27 ± 34.22a602.0 ± 40.50b322.21 ± 32.65b414.11 ± 35.33b505.20 ± 41.52b523.36 ± 36.66b
 GSH-Px (U/mg protein)3023 ± 2172236 ± 259a3111 ± 285b2567 ± 198b2758 ± 252b2904 ± 220b2808 ± 244b
 MDA (nmol/mg protein)9.03 ± 1.2516.91 ± 1.81a8.85 ± 1.33b14.28 ± 1.57b10.05 ± 1.01b9.66 ± 1.41b10.36 ± 1.55b
Pancreas
 GSH (μg/mg protein)444.08 ± 71.44294.14 ± 69.27a408.50 ± 66.85b312.58 ± 75.55360.00 ± 57.19c405.81 ± 63.36b406.16 ± 56.39b
 CAT (U/mg protein)298.02 ± 21.30174.22 ± 14.52a287.34 ± 22.71b196.35 ± 18.90b209.42 ± 23.00b212.56 ± 20.66b274.30 ± 21.94b
 SOD (U/mg protein)415.00 ± 33.20197.38 ± 36.55a385.52 ± 32.11b222.44 ± 36.40356.78 ± 37.80b379.91 ± 38.92b364.82 ± 40.24b
 GSH-Px (U/mg protein)658 ± 89462 ± 92a711 ± 101b555 ± 74c596 ± 94b623 ± 78b539 ± 79b
 MDA (nmol/mg protein)8.77 ± 1.0314.91 ± 1.44a8.05 ± 1.11b12.50 ± 1.48b10.87 ± 1.61b9.22 ± 1.31b8.99 ± 1.40b

Values are means ± SD for 10 rats in each group. N group: normal control; D group: diabetes group; N + G group: normal control plus GBE; D + LG group: diabetes plus low GBE treatment; D + MG group: diabetes plus middle GBE treatment; D + HG group: diabetes plus high GBE treatment; D + GLI group: diabetes plus glibenclamide treatment.
aIndicates statistical significance of compared to N group; b compared to D group.
c compared to D group.